Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Size

Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Analysis

The Benign Prostatic Hyperplasia Treatment Devices Market size is estimated at USD 1.64 billion in 2024, and is expected to reach USD 2.32 billion by 2029, growing at a CAGR of 7.20% during the forecast period (2024-2029).

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, commonly affecting men as they age. This condition can lead to urinary symptoms such as difficulty starting urination, weak urine flow, frequent urination, and the inability to empty the bladder completely. The BPH treatment devices market encompasses a range of medical devices designed to alleviate symptoms, reduce prostate size, and improve urinary function in patients with BPH. The BPH treatment devices market is experiencing significant growth due to the increasing prevalence of benign prostatic hyperplasia, technological advancements, and increased preference for minimally invasive treatments.

The rising prevalence of benign prostatic hyperplasia (BPH), particularly among men aged 40 and older, is a significant growth driver of the BPH treatment devices market. According to a study published in BMC Urology in November 2023, conducted in Homs, Syria, from January to March 2023, the prevalence of metabolic syndrome among BPH patients was 46.2%. The study revealed a strong association between metabolic syndrome and the severity of urinary symptoms as measured by the International Prostate Symptom Score (IPSS). Patients with metabolic syndrome exhibited higher IPSS scores, with 59.3% suffering from severe LUTS, compared to 36.2% of patients without metabolic syndrome.

Therefore, as the prevalence of BPH continues to rise, the demand for innovative and effective BPH treatment devices is expected to grow, driving market expansion.

Moreover, technological innovations, particularly in the field of robotics and minimally invasive procedures, have revolutionized the way BPH is treated, offering patients more precise, efficient, and less invasive options. For instance, a study published in Prostate International in June 2024 highlighted that a notable innovation in this area was the development of Aquablation, a robotic endoscopic platform specifically designed for BPH surgery. Aquablation uses a heat-free cavitating waterjet under real-time transrectal ultrasound guidance to execute resection plans that the surgeon pre-registers. This innovative approach is transformative, as it is effective for treating both small and large prostates, making it a versatile and valuable tool in BPH management. Thus, the rising adoption of such advanced technologies is enhancing patient outcomes and driving market growth.

The launch of advanced treatment devices in emerging markets underscores the increasing recognition of the benefits of minimally invasive procedures in managing BPH. For instance, in January 2023, Teleflex Incorporated commercially launched the UroLift System in India. This is a minimally invasive device designed to treat BPH, providing rapid symptom relief and enabling quick recovery. The introduction of the UroLift System in India marked a significant step forward in making advanced BPH treatment more accessible to patients in the region, reflecting the growing global demand for minimally invasive solutions. This is expected to drive the demand for benign prostatic hyperplasia (BPH) treatment devices over the next five years.

However, the high cost of advanced devices and lack of awareness and skilled professionals are expected to restrain market growth.